Heron Therapeutics (HRTX) closed at $0.29 on November 6, 2026, up 4.6% from the previous close, on volume of 1,151,264 shares (30-day average 1,978,420).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 14, 2026 | Calendar Put Spread | 16-Oct : 20-Nov-26 0.5 P | 41,908 |
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Heron Therapeutics Q3 Earnings Preview
Seeking Alpha News (Fri, 6-Nov 1:10 PM ET)
Heron Therapeutics to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026
Globe Newswire (Mon, 26-Oct 8:09 PM ET)
Heron Therapeutics Announces Second Quarter 2026 Financial Results
Globe Newswire (Mon, 10-Aug 8:00 AM ET)
Heron Therapeutics Projects Continued Growth as ZYNRELEF and APONVIE Drive Record Acute Care Revenue
Market Chameleon (Thu, 26-Feb 5:37 AM ET)
Market Chameleon (Fri, 9-Jan 6:15 AM ET)
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
Heron Therapeutics trades on the NASDAQ stock market under the symbol HRTX.
As of November 6, 2026, HRTX stock price climbed to $0.29 with 1,151,264 million shares trading.
HRTX has a beta of 3.16, meaning it tends to be more sensitive to market movements. HRTX has a correlation of 0.13 to the broad based SPY ETF.
HRTX has a market cap of $55.63 million. This is considered a Micro Cap stock.
Last quarter Heron Therapeutics reported $38 million in Revenue and -$.03 earnings per share. This fell short of revenue expectation by $-5 million and missed earnings estimates by -$.01.
In the last 3 years, HRTX traded as high as $3.93 and as low as $.26.
The top ETF exchange traded funds that HRTX belongs to (by Net Assets): VTI, IWM, VXF, VTWO, IWO.
HRTX has underperformed the market in the last year with a return of -73.4%, while the SPY ETF gained +10.8%. In the last 3 month period, HRTX fell short of the market, returning -41.3%, while SPY returned -4.1%. However, in the most recent 2 weeks HRTX has outperformed the stock market by returning -3.2%, while SPY returned -3.2%.
HRTX support price is $.26 and resistance is $.30 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HRTX shares will trade within this expected range on the day.
